Sign In
Buy CSTL
$20.39
+0.680 (+3.45%)
At Close: Jun 03, 2026
FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from
Castle Biosciences Celebrates Skin Cancer Awareness Month
07:00am, Wednesday, 07'th May 2025
Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month
Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript
10:58pm, Monday, 05'th May 2025
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations and Corporate Affairs Derek
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
06:20pm, Monday, 05'th May 2025
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.09 per share a year ago.
Castle Biosciences Reports First Quarter 2025 Results
04:06pm, Monday, 05'th May 2025
Q 1 2025 revenue increased 21% over Q 1 2024 to $88 million Q 1 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, DecisionDx ® -SCC, TissueCypher ® ) increased 33% over
Castle Biosciences to Acquire Previse
04:05pm, Monday, 05'th May 2025
Expected to complement Castle's current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development F
Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines' 5% threshold to f
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
07:00am, Monday, 28'th Apr 2025
FRIENDSWOOD, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its achiev
FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research int
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
07:00am, Tuesday, 08'th Apr 2025
FRIENDSWOOD, Texas, April 08, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key education
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
07:00am, Monday, 07'th Apr 2025
FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it ha
Consistent with prior studies, published results from Castle's DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivit
Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress.
New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantl
